

Applicants: David Baltimore et al.
Serial No.: 10/037,341
Filed : January 4, 2002
Page 14 of 47

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

In accordance with their duty of disclosure under 37 C.F.R. §1.555, applicants direct the Examiner's attention to the following disclosures, which are listed on Form PTO-1449 (**Exhibit B**). Copies of all of the documents listed have been submitted in connection with U.S. Patent No. 6,410,516 and its in reexamination proceedings (*Ex Parte* reexamination Control Nos. 90/007,503, filed April 4, 2005, and 90/007,828, filed December 2, 2005), which documents are publicly available. The subject application claims benefit of the filing date of U.S. Patent No. 6,410,561 under 35 U.S.C. §120. Accordingly, copies of items 1-242 are not attached to this Supplemental Information Disclosure Statement but are readily available to the Examiner and to the public from the file history of U.S. Patent No. 6,410,516.

1. June 9, 2006 Complaint, *Ariad Pharmaceuticals, Inc. V. Jon W. Dudas*, Civil Action 1:06cv679 (CMH/BRP);
2. July 12, 2006 Notice of Hearing, *Ariad Pharmaceuticals, Inc. V. Jon W. Dudas*, Civil Action 1:06cv679 (CMH/BRP);
3. August 2, 2006 Memorandum Of Law In Support Of Defendant's Motion To Dismiss Or In The Alternative For Summary Judgement And Opposition To Plaintiffs' Motion For Summary Judgment, *Ariad Pharmaceuticals, Inc. V. Jon W. Dudas*, Civil Action 1:06cv679 (CMH/BRP);
4. August 2, 2006 Statement Regarding Eli Lilly & Company's Motion To Intervene And For Leave To File, *Ariad*

Applicants: David Baltimore et al.
Serial No.: 10/037,341
Filed : January 4, 2002
Page 15 of 47

- Pharmaceuticals, Inc. V. Jon W. Dudas, Civil Action 1:06cv679 (CMH/BRP);*
5. August 14, 2006 Notice Of Filing, *Ariad Pharmaceuticals, Inc. V. Jon W. Dudas, Civil Action 1:06cv679 (CMH/BRP);*
 6. August 14, 2006 Plaintiffs' Brief in Opposition To Motion To Intervene By Eli Lilly and Company, *Ariad Pharmaceuticals, Inc. V. Jon W. Dudas, Civil Action 1:06cv679 (CMH/BRP);*
 7. August 14, 2006 Plaintiffs' Brief In Reply To Defendant's Motion To Dismiss Or In the Alternative For Summary Judgment And Opposition To Plaintiffs' Motion For Summary Judgment, *Ariad Pharmaceuticals, Inc. V. Jon W. Dudas, Civil Action 1:06cv679 (CMH/BRP);*
 8. August 28, 2006 Reply Memorandum In Support Of Defendant's Motion To Dismiss, Or, In the Alternative, For Summary Judgment, *Ariad Pharmaceuticals, Inc. V. Jon W. Dudas, Civil Action 1:06cv679;*
 9. October 3, 2006 Order (Defendant's Motion to Dismiss), *Ariad Pharmaceuticals, Inc. V. Jon W. Dudas, Civil Action 1:06cv679;*
 10. October 3, 2006 Order (Eli Lilly & Company's Motion to Intervene), *Ariad Pharmaceuticals, Inc. V. Jon W. Dudas, Civil Action 1:06cv679;*
 11. August 2, 2006 Defendant Eli Lilly And Company's Pre-Trial Brief, *Ariad Pharmaceuticals, Inc. V. Eli Lilly and Company, Civil Case 02 CV 11280 RWZ;*

Applicants: David Baltimore et al.
Serial No.: 10/037,341
Filed : January 4, 2002
Page 16 of 47

12. August 2, 2006 Plaintiffs' Supplemental Trial Brief, *Ariad Pharmaceuticals, Inc. V. Eli Lilly and Company*, Civil Case 02 CV 11280 RWZ;
13. September 11, 2006 Plaintiffs' Proposed Findings of Fact and Conclusions of Law on the issues of Inequitable Conduct, Indefiniteness, Prosecution Laches, and Non-Patentable Subject Matter, *Ariad Pharmaceuticals, Inc. V. Eli Lilly and Company*, Civil Case 02 CV 11280 RWZ;
14. September 11, 2006 Lilly's Post-Trial Proposed Findings of Fact And Conclusions Of Law Relating To (1) Invalidity Under 35 U.S.C. §101, (2) Unenforceability For Inequitable Conduct, And (3) Unenforceability For Prosecution Laches, *Ariad Pharmaceuticals, Inc. V. Eli Lilly and Company*, Civil Case 02 CV 11280 RWZ;
15. September 29, 2006 Plaintiffs' Reply To Lilly's Proposed Findings of Fact And Conclusions of Law On the Issues of (1) Patentability Under 35 U.S.C. §010, (2) Inequitable Conduct, and (3) Prosecution Laches, *Ariad Pharmaceuticals, Inc. V. Eli Lilly and Company*, Civil Case 02 CV 11280 RWZ;
16. September 29, 2006 Lilly's Response To Ariad's Proposed Findings of Facts And Conclusions of Law, *Ariad Pharmaceuticals, Inc. V. Eli Lilly and Company*, Civil Case 02 CV 11280 RWZ;
17. April 20, 2006 Complaint For Declaratory Judgment Of Patent Invalidity And Non-Infringement, *Amgen, Inc. V. Ariad Pharmaceuticals, Inc.*, Civil Action No. ____ ;
18. April 20, 2006 Civil Cover Sheet, *Amgen, Inc. V. Ariad Pharmaceuticals, Inc.*, Civil Action CA ____ ;

Applicants: David Baltimore et al.
Serial No.: 10/037,341
Filed : January 4, 2002
Page 17 of 47

19. April 20, 2006 Report On The Filing or Determination of an Action Regarding a Patent or Trademark, *Amgen, Inc. V. Ariad Pharmaceuticals, Inc.*, Civil Action CA 06-259;
20. June 14, 2006 Defendant Ariad Pharmaceuticals, Inc.'s Motion To Dismiss For Lack of Subject Matter Jurisdiction, Failure To State a Claim, And Failure To Join Indispensable Parties, *Amgen, Inc. V. Ariad Pharmaceuticals, Inc.*, Civil Action 06-259-KAJ;
21. June 14, 2006 Declaration of Laurie A. Allen (including Exhibits A-D), *Amgen, Inc. V. Ariad Pharmaceuticals, Inc.*, Civil Action 06-259-KAJ;
22. June 14, 2006 Defendant Ariad Pharmaceuticals, Inc.'s Opening Memorandum of Law In Support Of Its Motion To Dismiss For Lack of Subject Matter Jurisdiction, Failure To State A Claim For which Relief May Be Granted, And Failure To Join Indispensable Parties (including Tab 1), *Amgen, Inc. V. Ariad Pharmaceuticals, Inc.*, Civil Action 06-259-KAJ;
23. June 28, 2006 Declaration of Paul Cantrell, Esq. Signed May 18, 2006, *Amgen, Inc. V. Ariad Pharmaceuticals, Inc.*, Civil Action No. 1:06-cv-259 (KAJ);
24. June 28, 2006 Declaration of Melanie K. Sharp (including Exhibits A-L), *Amgen, Inc. V. Ariad Pharmaceuticals, Inc.*, Civil Action No. 1:06-cv-259 (KAJ);
25. June 26, 2006 Declaration of Frank Ungemach (including Exhibits A-H), *Amgen, Inc. V. Ariad Pharmaceuticals, Inc.*, Civil Action No. 1:06-cv-259 (KAJ);

Applicants: David Baltimore et al.
Serial No.: 10/037,341
Filed : January 4, 2002
Page 18 of 47

26. June 28, 2006 Plaintiffs' Opposition To Ariad's Motion To Dismiss For Lack of Subject Matter Jurisdiction, Failure To State a Claim, And Failure to Join Indispensable Parties (including Exhibits A-D unreported cases), *Amgen, Inc. V. Ariad Pharmaceuticals, Inc.*, Civil Action 06-259-KAJ;
27. July 12, 2006 Declaration of Fritz Casselman, *Amgen, Inc. V. Ariad Pharmaceuticals, Inc.*, Civil Action 06-259-KAJ;
28. July 13, 2006 Declaration of Patricia Carson, *Amgen, Inc. V. Ariad Pharmaceuticals, Inc.*, Civil Action 06-259-KAJ;
29. July 13, 2006 Defendant Ariad Pharmaceuticals, Inc.'s Reply Memorandum of Law In Support of its Motion to Dismiss For Lack of Subject Matter Jurisdiction, Failure to State a Claim For Which Relief May Be Granted, And Failure To Join Necessary And Indispensable Parties, *Amgen, Inc. V. Ariad Pharmaceuticals, Inc.*, Civil Action 06-259-KAJ;
30. July 12, 2006 Supplemental Declaration of Laurie A. Allen, *Amgen, Inc. V. Ariad Pharmaceuticals, Inc.*, Civil Action 06-259-KAJ;
31. Proposed Final Pretrial Order, *Amgen, Inc. V. Ariad Pharmaceuticals, Inc.*, Civil Action 06-259-KAJ;
32. July 19,, 2006 Scheduling Order, *Amgen, Inc. V. Ariad Pharmaceuticals, Inc.*, Civil Action 06-259-KAJ;
33. July 19, 2006 Trial Management Order, *Amgen, Inc. V. Ariad Pharmaceuticals, Inc.*, Civil Action 06-259-KAJ;
34. July 21, 2006 Letter to Judge Jordan from Melanie K. Sharp of Young Conaway Stargatt & Taylor, LLP, *Amgen, Inc. V. Ariad Pharmaceuticals, Inc.*, Civil Action 06-259-KAJ;

Applicants: David Baltimore et al.
Serial No.: 10/037,341
Filed : January 4, 2002
Page 19 of 47

35. July 25, 2006 Letter to Judge Jordan from Steven J. Balick of Ashby & Geddes, *Amgen, Inc. V. Ariad Pharmaceuticals, Inc.*, Civil Action 06-259-KAJ;
36. August 30, 2006 Letter to Judge Jordan from Steven J. Balick of Ashby & Geddes (including Exhibits A & B), *Amgen, Inc. V. Ariad Pharmaceuticals, Inc.*, Civil Action 06-259-KAJ;
37. August 31, 2006 Letter to Judge Jordan from Melanie K. Sharp of Young Conaway Stargatt & Taylor, LLP (including Exhibits 1 & 2), *Amgen, Inc. V. Ariad Pharmaceuticals, Inc.*, Civil Action 06-259-KAJ;
38. September 13, 2006 Order, *Amgen, Inc. V. Ariad Pharmaceuticals, Inc.*, Civil Action 06-259-KAJ;
39. September 25, 2006 Defendant Ariad Pharmaceuticals, Inc.'s Motion Certification Pursuant to 28 U.S.C. §1292(b), *Amgen, Inc. V. Ariad Pharmaceuticals, Inc.*, Civil Action 06-259-KAJ;
40. September 25, 2006 Defendant Ariad Pharmaceuticals Inc.'s Opening Memorandum of Law In Support of Its Motion For Certification Pursuant To 28 U.S.C. §1292(b), *Amgen, Inc. V. Ariad Pharmaceuticals, Inc.*, Civil Action 06-259-KAJ;
41. September 25, 2006 Ariad Pharmaceuticals, Inc.'s Answer To Compliant, *Amgen, Inc. V. Ariad Pharmaceuticals, Inc.*, Civil Action 06-259-KAJ;
42. September 25, 2006 Declaration of Elizabeth L. Rosenblatt In Support of Ariad Pharmaceuticals, Inc.'s Motion For Certification Pursuant To 28 U.S.C. §1292(b) (including

Applicants: David Baltimore et al.
Serial No.: 10/037,341
Filed : January 4, 2002
Page 20 of 47

- Exhibits A-Q), *Amgen, Inc. V. Ariad Pharmaceuticals, Inc.*, Civil Action 06-259-KAJ;
43. October 2, 2006 Ariad Opposition Ex. A-C, *Amgen, Inc. V. Ariad Pharmaceuticals, Inc.*, Civil Action 06-259-KAJ;
 44. October 10, 2006 Plaintiffs' Memorandum in Opposition To Ariad's Motion For Certification Pursuant to 28 U.S.C. §1292(b), *Amgen, Inc. V. Ariad Pharmaceuticals, Inc.*, Civil Action 06-259-KAJ;
 45. October 10, 2006 Amgen Appendix of Exhibits 1-2 To Plaintiffs' Memorandum in Opposition To Ariad's Motion For Certification Pursuant to 28 U.S.C. §1292(B), *Amgen, Inc. V. Ariad Pharmaceuticals, Inc.*, Civil Action 06-259-KAJ;
 46. October 12, 2006 Order, *Amgen, Inc. V. Ariad Pharmaceuticals, Inc.*, Civil Action 06-259-KAJ;
 47. October 17, 2006 Defendant Ariad Pharmaceuticals, Inc.'s Reply Memorandum of Law In Support Of Its Motion For Certification Pursuant To 28 U.S.C. §1292(b), *Amgen, Inc. V. Ariad Pharmaceuticals, Inc.*, Civil Action 06-259-KAJ;
 48. November 3, 2006 Order, *Amgen, Inc. V. Ariad Pharmaceuticals, Inc.*, Civil Action 06-259-KAJ;
 49. July 7, 2006 Plaintiffs' First Set of Interrogatories to Defendant, *Amgen, Inc. V. Ariad Pharmaceuticals, Inc.*, Civil Action 06-259-KAJ;
 50. July 7, 2006 Plaintiffs' First Set of Requests for Production of Documents and Things to Defendant, *Amgen, Inc. V. Ariad Pharmaceuticals, Inc.*, Civil Action 06-259-KAJ;

Applicants: David Baltimore et al.
Serial No.: 10/037,341
Filed : January 4, 2002
Page 21 of 47

51. July 26, 2006 Defendant's Rule 26(a)(1) Initial Disclosure, *Amgen, Inc. V. Ariad Pharmaceuticals, Inc.*, Civil Action 06-259-KAJ;
52. July 26, 2006 Plaintiffs' Initial Disclosures Pursuant to Federal Rule of Civil Procedure 26(a)(1), *Amgen, Inc. V. Ariad Pharmaceuticals, Inc.*, Civil Action 06-259-KAJ;
53. August 7, 2006 Defendant Ariad Pharmaceuticals, Inc.'s Responses And Objections to Plaintiffs' First Set of Requests For Production of Documents and Things to Defendant, *Amgen, Inc. V. Ariad Pharmaceuticals, Inc.*, Civil Action 06-259-KAJ;
54. September 27, 2006 Defendant Ariad Pharmaceuticals, Inc.'s First Supplemental Responses And Objections To Plaintiffs' First Set of Requests for Production of Documents And Things to Defendant, *Amgen, Inc. V. Ariad Pharmaceuticals, Inc.*, Civil Action 06-259-KAJ;
55. August 7, 2006 Defendant Ariad Pharmaceuticals, Inc.'s Responses And Objections To Plaintiff Amgen, Inc.'s First Set of Interrogatories to Defendant, *Amgen, Inc. V. Ariad Pharmaceuticals, Inc.*, Civil Action 06-259-KAJ;
56. September 27, 2006 Defendant Ariad Pharmaceuticals, Inc.'s First Supplemental Responses and Objections To Plaintiffs' First Set Of Requests for Production of Documents and Things to Defendant, *Amgen, Inc. V. Ariad Pharmaceuticals, Inc.*, Civil Action 06-259-KAJ;
57. October 11, 2006 Defendant Ariad Pharmaceuticals, Inc.'s First Supplemental Responses and Objections to Plaintiff Amgen, Inc.'s First Set of Interrogatories to Defendant,

Applicants: David Baltimore et al.
Serial No.: 10/037,341
Filed : January 4, 2002
Page 22 of 47

- Amgen, Inc. V. Ariad Pharmaceuticals, Inc.*, Civil Action 06-259-KAJ;
58. October 26, 2006 Stipulated Protective Order Pursuant To Federal Rule of Civil Procedure 26(c), *Amgen, Inc. V. Ariad Pharmaceuticals, Inc.*, Civil Action 06-259-KAJ;
 59. July 12, 2006 Telephone Conference before Honorable Kent A. Jordan, U.S.D.C.J., *Amgen, Inc. V. Ariad Pharmaceuticals, Inc.*, Civil Action 06-259-KAJ;
 60. September 11, 2006 Motions Hearing before Honorable Kent A. Jordan, U.S.D.C.J., *Amgen, Inc. V. Ariad Pharmaceuticals, Inc.*, Civil Action 06-259-KAJ;
 61. November 3, 2006 Motion Hearing before Honorable Kent A. Jordan, U.S.D.C.J., *Amgen, Inc. V. Ariad Pharmaceuticals, Inc.*, Civil Action 06-259-KAJ;
 62. January 22, 2007 Declaration of Elizabeth L. Rosenblatt in Support of Ariad Pharma., Inc.'s Motion to Stay Litigation Pending Conclusion of Reexamination Proceedings in the Patent and Trademark Office, *Amgen, Inc. et al. v. Ariad Pharma., Inc.*, CA No. 06-259-*** (MPT);
 63. January 23, 2007 Defendant Ariad Pharma., Inc.'s Motion to Stay Litigation Pending Conclusion of Reexamination Proceedings in the Patent and Trademark Office, *Amgen, Inc. et al. v. Ariad Pharma., Inc.*, CA No. 06-259-*** (MPT);
 64. January 23, 2007 Defendant Ariad Pharma., Inc.'s Opening Memorandum of Law in Support of Its Motion to Stay Litigation Pending Conclusion of Reexamination Proceedings in the Patent and Trademark Office (including Exhibits A-

Applicants: David Baltimore et al.
Serial No.: 10/037,341
Filed : January 4, 2002
Page 23 of 47

- G), *Amgen, Inc. et al. v. Ariad Pharma., Inc.*, CA No. 06-259-*** (MPT);
65. January 31, 2007 Plaintiffs' First Set of Requests for Admission to Defendant, *Amgen, Inc. et al. v. Ariad Pharma., Inc.*, CA No. 06-259-*** (MPT);
66. February 20, 2007 Transcript of Oral Argument Hearing before Hon. Mary Pat Thyng, U.S. Magistrate Judge, *Amgen, Inc. et al. v. Ariad Pharma., Inc.*, CA No. 06-259-*** (MPT);
67. February 22, 2007 Defendant Ariad Pharma., Inc.'s First Set of Requests for Production of Documents, *Amgen, Inc. et al. v. Ariad Pharma., Inc.*, CA No. 06-259-MPT;
68. February 22, 2007 Defendant Ariad Pharma., Inc.'s First Set of Interrogatories, *Amgen, Inc. et al. v. Ariad Pharma., Inc.*, CA No. 06-259-MPT;
69. March 7, 2007 Defendant Ariad Pharma., Inc.'s Responses and Objections to Plaintiffs' First Set of Requests for Admission to Defendant, *Amgen, Inc. et al. v. Ariad Pharma., Inc.*, CA No. 06-259-MPT;
70. March 26, 2007 Plaintiffs' Responses to Defendant's First Set of Requests for Production of Documents, *Amgen, Inc. et al. v. Ariad Pharma., Inc.*, CA No. 06-259-MPT;
71. March 26, 2007 Plaintiffs' Responses and Objections to Ariad's First Set of Interrogatories, *Amgen, Inc. et al. v. Ariad Pharma., Inc.*, CA No. 06-259-MPT;
72. April 3, 2007 Plaintiffs' Multi-Media Materials (Technology Tutorial), *Amgen, Inc. et al. v. Ariad Pharma., Inc.*, CA No. 06-259-MPT;

Applicants: David Baltimore et al.
Serial No.: 10/037,341
Filed : January 4, 2002
Page 24 of 47

73. April 3, 2007 Notice of Filing of Multi-Media Materials (Plaintiffs' Technology Tutorial), *Amgen, Inc. et al. v. Ariad Pharma., Inc.*, CA No. 06-259-MPT;
74. April 3, 2007 Notice of Filing of Multimedia Materials (including Tabs A and B), *Amgen, Inc. et al. v. Ariad Pharma., Inc.*, CA No. 06-259-MPT;
75. April 3, 2007 Ariad Pharma., Inc. Technology Tutorial, *Amgen, Inc. et al. v. Ariad Pharma., Inc.*, CA No. 06-259-MPT;
76. April 12, 2007 Defendant Ariad Pharma., Inc.'s Second Supplemental Responses and Objections to Plaintiffs' First Set of Interrogatories to Defendant, *Amgen, Inc. et al. v. Ariad Pharma., Inc.*, CA No. 06-259-MPT;
77. April 13, 2007 Amended Complaint for Declaratory Judgment of Patent Invalidity and Non-Infringement, *Amgen, Inc. et al. v. Ariad Pharma., Inc.*, CA No. 06-259-MPT;
78. April 13, 2007 Second Amended Complaint for Declaratory Judgment of Patent Invalidity and Non-Infringement, and Unenforceability, *Amgen, Inc. et al. v. Ariad Pharma., Inc.*, CA No. 06-259-MPT;
79. April 13, 2007 Answer to Amended Complaint, Counterclaim and Demand for Jury Trial, *Amgen, Inc. et al. v. Ariad Pharma., Inc.*, CA No. 06-259-MPT;
80. April 17, 2007 Letter to Judge Thyng from Steven J. Balick, Esq., *Amgen, Inc. et al. v. Ariad Pharma., Inc.*, CA No. 06-259-MPT;
81. April 19, 2007 Defendant and Counterclaim Plaintiff Ariad's Second Set of Requests for Production of Documents to

Applicants: David Baltimore et al.
Serial No.: 10/037,341
Filed : January 4, 2002
Page 25 of 47

- Amgen, *Amgen, Inc. et al. v. Ariad Pharma., Inc.*, CA No. 06-259-MPT;
82. April 20, 2007 Defendant Ariad Pharma., Inc.'s First Supplemental Responses and Objections to Plaintiffs' First Set of Requests for Admission to Defendant, *Amgen, Inc. et al. v. Ariad Pharma., Inc.*, CA No. 06-259-MPT;
 83. April 23, 2007 Plaintiffs' First Supplemental Responses and Objections to Ariad's First Set of Interrogatories, *Amgen, Inc. et al. v. Ariad Pharma., Inc.*, CA No. 06-259-MPT;
 84. May 1, 2007 Amgen's Technology Tutorial, *Amgen, Inc. et al. v. Ariad Pharma., Inc.*, CA No. 06-259-MPT;
 85. May 1, 2007 Ariad Pharma., Inc. Technology Tutorial, *Amgen, Inc. et al. v. Ariad Pharma., Inc.*, CA No. 06-259-MPT;
 86. May 1, 2007 Transcript of Tutorial Hearing before Hon. Mary Pat Thyng, U.S. Magistrate Judge, *Amgen, Inc. et al. v. Ariad Pharma., Inc.*, CA No. 06-259-MPT;
 87. May 3, 2007 Amgen Entities' Reply to Ariad, Harvard, MIT, and Whitehead's Counterclaim, *Amgen, Inc. et al. v. Ariad Pharma., Inc.*, CA No. 06-259-MPT;
 88. Bottero et al. (2006) "NF- κ B and the regulation of hematopoiesis," *Cell Death and Differentiation*, 13: 785-797;
 89. Doucas et al. (2000) "Cytoplasmic catalytic subunit of protein kinase A mediates cross-repression by NF- κ B and the glucocorticoid receptor," *PNAS*, 97(22): 11893-11898;
 90. Withoff, S. et al. "Regulating the Master Regulator NF- κ B: From Natural Strategies to Rationally Designed Superdrugs."

Applicants: David Baltimore et al.
Serial No.: 10/037,341
Filed : January 4, 2002
Page 26 of 47

- in: Ghosh, S., *Handbook of Transcription Factor NF-kappaB* (Boca Raton, FL, CRC Press, 2007), pp. 195-211;
91. Berry et al., "1 α , 25-Dihydroxyvitamin D₃ Stimulates Phosphorylation of I κ B α and Synergizes with TPA to Induce Nuclear Translocation of NF κ B during Monocytic Differentiation of NB4 Leukemia Cells, *Experimental Cell Research* 272, 176-184 (2002);
 92. Lepper et al., "Clinical implications of antibiotic-induced endotoxin release in septic shock", *Intensive Care Med* (2002), 28:824-833;
 93. Shenep and Mogan, "Kinetics of Endotoxin Release During Antibiotic Therapy For Experimental Gram-Negative Bacterial Sepsis", *The Journal of Infectious Diseases*, Vol. 150, No. 3, (1984) 380-388;
 94. July 6, 2007 Finding of Facts And Conclusions of Law, *Ariad Pharmaceuticals, Inc. v. Eli-Lilly & Co.*, U.S. District Court, District of Massachusetts, CV-02-11280-RWZ
 95. April 17, 2007 Deposition of Harvey J. Berger, M.D., *Amgen, Inc. et al. v. Ariad Pharmaceuticals, Inc. et al.*, D. Del. Civil Action No. 06-259-MPT;
 96. April 20, 2007 Videotaped Deposition of Chen-Ming Fan, *Amgen, Inc. et al. v. Ariad Pharmaceuticals, Inc. et al.*, D. Del. Civil Action No. 06-259-MPT;
 97. April 24, 2007 Videotaped Deposition of Jonathan H. Lebowitz, Ph.D., *Amgen, Inc. et al. v. Ariad Pharmaceuticals, Inc. et al.*, D. Del. Civil Action No. 06-259-MPT;

Applicants: David Baltimore et al.
Serial No.: 10/037,341
Filed : January 4, 2002
Page 27 of 47

98. April 27, 2007 Videotaped Deposition of Harinder Singh, Ph.D., Amgen, Inc. et al. v. Ariad Pharmaceuticals, Inc. et al., D. Del. Civil Action No. 06-259-MPT;
99. May 3, 2007 Videotaped Deposition of Ranjan Sen, Ph.D., Amgen, Inc. et al. v. Ariad Pharmaceuticals, Inc. et al., D. Del. Civil Action No. 06-259-MPT;
100. May 16, 2007 Videotaped Deposition of Phillip A. Sharp, Ph.D., Amgen, Inc. et al. v. Ariad Pharmaceuticals, Inc. et al., D. Del. Civil Action No. 06-259-MPT;
101. May 25, 2007 Videotaped Deposition of Albert S. Baldwin, Jr., Ph.D., Amgen, Inc. et al. v. Ariad Pharmaceuticals, Inc. et al., D. Del. Civil Action No. 06-259-MPT;
102. June 7, 2007 Videotaped Deposition of Michael J. Lenardo, M.D., Amgen, Inc. et al. v. Ariad Pharmaceuticals, Inc. et al., D. Del. Civil Action No. 06-259-MPT;
103. May 8, 2007 Defendant Ariad Pharmaceuticals, Inc.'s Third Supplemental Responses and Objections To Plaintiffs' First Set Of Interrogatories To Defendant, Amgen, Inc. et al. v. Ariad Pharmaceuticals, Inc. et al., D. Del. Civil Action No. 06-259-MPT;
104. May 30, 2007 Defendant Ariad Pharmaceuticals, Inc.'s Second Supplemental Responses And Objections To Plaintiff's First Set of Requests For Admission To Defendant, Amgen, Inc. et al. v. Ariad Pharmaceuticals, Inc. et al., D. Del. Civil Action No. 06-259-MPT;
105. May 30, 2007 letter to Judge Thyng from Melanie K. Sharp of Young Conaway Stargatt & Taylor, LLP, Amgen, Inc. et al.

Applicants: David Baltimore et al.
Serial No.: 10/037,341
Filed : January 4, 2002
Page 28 of 47

- v. Ariad Pharmaceuticals, Inc. et al., D. Del. Civil Action No. 06-259-MPT;
106. May 31, 2007 letter to Judge Thyng from Steven J. Balick of Ashby & Geddes, Amgen, Inc. et al. v. Ariad Pharmaceuticals, Inc. et al., D. Del. Civil Action No. 06-259-MPT;
107. June 5, 2007 Wyeth's Reply To Ariad Pharmaceuticals, Inc., Massachusetts Institute of Technology, The President And Fellows of Harvard College, and The Whitehead Institute for Biomedical Research's Counterclaim, Amgen, Inc. et al. v. Ariad Pharmaceuticals, Inc. et al., D. Del. Civil Action No. 06-259-MPT;
108. June 14, 2007 Amgen Entities' Second Supplemental Responses And Objections To Ariad's First Set of Interrogatories: NOS. 1, 2, 5, 6 & 12, Amgen, Inc. et al. v. Ariad Pharmaceuticals, Inc. et al., D. Del. Civil Action No. 06-259-MPT;
109. Abramson, S. et al., "Modes of action of aspirin-like drugs", Proc. Natl. Acad. Sci. USA (1985) 82:7227-7231;
110. Baeuerle, P.A., "The Inducible Transcription Activator NF- κ B: Regulation by Distinct Protein Subunits", Biochimica Biophysica. Acta. (1991) 1072:63-80;
111. Baldwin, A.S., "Two Transcription Factors, NF- κ B and H2TF1, Interact With a Single Regulatory Sequence In the Class I major Histocompatibility Complex Promoter", Proc. Natl. sci. USA, (1988) 85:723-727;

Applicants: David Baltimore et al.
Serial No.: 10/037,341
Filed : January 4, 2002
Page 29 of 47

112. Beutler, B. et al., "Control of Cachectin (Tumor Necrosis Factor) Synthesis: Mechanisms of Endotoxin Resistance", Science (1986) 232:977-980;
113. Bielinska, A. et al., "Regulation of Gene Expression with Double-Stranded Phosphorothioate Oligonucleotides", Science (1990) 250:997-1000;
114. Brini, A.T., et al., "Cyclosporin A inhibits induction of IL-2 receptor α chain expression by affecting activation of NF- κ B-like factor(s) in cultured human T lymphocytes", Eur. Cytokine Net. (1990) 1:131-139;
115. Chedid, M. And Mizel, S.B., "Involvement of Cyclic AMP-Dependent Protein Kinases in the Signal Transduction Pathway for Interleukin-1" Molecular And Cellular Biology (1990) 10:3824-3827;
116. Colston, K. et al. "1, 25-Dihydroxyvitamin D3 and Malignant Melanoma: The Presence of Receptors and Inhibition of Cell Growth in Culture" Endocrinology (1981) 108:1083-1086;
117. Devary, Y. et al., "NF- κ B Activation by Ultraviolet Light Not Dependent on a Nuclear Signal" Science (1993) 261:1442-1445;
118. Dew, MJ, "Maintenance of remission in ulcerative colitis with 5-amino salicylic acid in high doses by mouth" British Medical Journal (1983) 287:23-24;
119. Dobrilla, G. et al., "Is Ethanol Metabolism Affected by Oral Administration of Cimetidine and Ranitidine at Therapeutic Doses?" Hepato-gastroenterol (1984) 31:35-37;

Applicants: David Baltimore et al.
Serial No.: 10/037,341
Filed : January 4, 2002
Page 30 of 47

120. Eck, S.D. et al., "Inhibition of Phorbol Ester-Induced Cellular Adhesion by Competitive Binding of NF- κ B In Vivo" *Molecular and Cellular Biology* (1993) 13:6530-6536;
121. Edbrooke, M.R. et al., "Identification of *cis*-Acting Sequences Responsible for Phorbol Ester Induction of Human Serum Amyloid A Gene Expression via a Nuclear Factor κ B-Like Transcription Factor" *Molecular and Cellular Biology* (1989) 9:1908-1916;
122. Emmel, E.A. et al., "Cyclosporin A Specifically Inhibits Function of Nuclear Proteins Involved in T Cell Activation" *Science* (1989) 246:1617-1620;
123. Giri, J.G. et al., "Interleukin 1-Mediated Induction of κ -Light Chain Synthesis And Surface Immunoglobulin Expression of Pre-B Cells" *The Journal of Immunology* (1984) 132:223-228;
124. Gray, T.K. et al., "17 β -Estradiol acts directly on the clonal osteoblastic cell line UMR106" *Proc. Natl. Acad. Sci. USA* (1987) 84:6267-6271;
125. Griffith [1], B.P., et al., "Targeted blood levels of cyclosporine for cardiac transplantation" *J. Thorac Cardiovasc Surg* (1984) 88:952-957;
126. Griffith [2], B.P., et al., "Cardiac Transplantation with Cyclosporin A and Prednisone" *Ann. Surg.* (1982) 196:324-329;
127. Hahn, E.O. et al., "Effect of Cortisone on Acute Streptococcal Infections And Post-Streptococcal Complications¹" *Streptococcal Disease Laboratory* (1950) pp. 274-281;

Applicants: David Baltimore et al.
Serial No.: 10/037,341
Filed : January 4, 2002
Page 31 of 47

128. Holick, M.F. et al., "Identification of 1,25-Dihydroxycholecalciferol, a Form of Vitamin D₃ Metabolically Active in the Intestine" Proc. Nat. Acad. Sci. USA (1971) 68:803-804;
129. Hoyos, B. Et al., "Kappa B-Specific DNA Binding Proteins: Role in the Regulation of Human Interleukin-2 Gene Expression" Science (1989) 244:457-460;
130. Jones, A.W., "Elimination Half-life of Methanol During Hangover" Pharmacology & Toxicology (1987) 60:217-220;
131. Kohase, M. et al., "Dexamethasone Inhibits Feedback Regulation of the Mitogenic Activity of Tumor Necrosis Factor, Interleukin-1, and Epidermal Growth Factor in Human Fibroblasts" Journal of Cellular Physiology (1987) 132:271-278;
132. Koizumi, T. et al., "Inhibitors of IL-2 Production and IL-2 Receptor Expression in Human Leukemic T-Cell Line, Jurkat¹" Cellular Immunology (1986) 103:469-475;
133. Kovacs, E.J., et al., "Differential Inhibition of IL-1 and TNF- α mRNA Expression By Agents Which Block Second Messenger Pathways In Murine Macrophages¹" The Journal of Immunology (1988) 141:3101-3105;
134. Krönke, M. et al., "Cyclosporin A Inhibits T-cell Growth Factor Gene Expression At the Level of mRNA Transcription", Proc. Natl. Acad. Sci. USA (1984) 81:5214-5218;
135. Lawson, D.E.M., et al., "Identification of 1,25-Dihydroxycholecalciferol, a New Kidney Hormone controlling Calcium Metabolism" Nature (1971) 230:228-230;

Applicants: David Baltimore et al.
Serial No.: 10/037,341
Filed : January 4, 2002
Page 32 of 47

136. Lemire, J.M., et al., "1,25-Dihydroxyvitamin D₃ Suppresses Human T Helper/Inducer Lymphocyte Activity in Vitro¹" The Journal of Immunology (1985) 134:3032-3035;
137. Lemire [2], J.M. et al., "1 α ,25-Dihydroxyvitamin D₃ Suppresses Proliferation and Immunoglobulin Production by Normal Human Peripheral Blood Mononuclear Cells", J. Clin. Invest. (1984) 74:657-661;
138. Lipsky, P.E. et al., "The Role of Interleukin 1 in Human B Cell Activation: Inhibition of B Cell Proliferation and the Generation of Immunoglobulin-Secreting Cells By An Antibody Against Human Leukocytic Pyrogen¹" The Journal of Immunology (1983) 130:2708-2714;
139. Männel, D.N., et al., "Inhibition of Nonspecific Tumoricidal Activity by Activated Macrophages with Antiserum Against a Soluble Cytotoxic Factor" Infection And Immunity (1981) 33:156-164;
140. Manolagas [1], S.C. et al., "The Antiproliferative Effect of Calcitriol on Human Peripheral Blood Mononuclear Cells" Journal of Clinical Endocrinology and Metabolism (1986) 63:394-400;
141. Manolagas [2], S.C. et al., Estrogen, Cytokines, and the Control of Osteoclast Formation and Bone Resorption In Vitro and In Vivo" Osteoporosis Int (1993) Suppl. 1:S114-116;
142. Matthews [1], N., "Human Monocyte Killing of Tumor Cells: Contribution of an Extracellular Cytotoxin" Department of Medical Microbiology (1982) 721-729;

Applicants: David Baltimore et al.
Serial No.: 10/037,341
Filed : January 4, 2002
Page 33 of 47

143. Matthews [2], N., "Effect on human monocyte killing of tumour cells of antibody raised against an extracellular monocyte cytotoxin" *Immunology* (1983) 48:321-327;
144. Meichle A. et al., "Protein Kinase C-independent Activation of Nuclear Factor κ B by Tumor Necrosis Factor" *The Journal of Biological Chemistry* (1990) 265:8339-8343;
145. Mihm [1], S. And Droge, W., "Intracellular Glutathione Level Controls DNA-Binding Activity of NF- κ B-Like Protein(s)" *Institute of Immunology and Genetics, German Cancer Research Center, S.A.311*;
146. Mihm [2], S. et al., "Inhibition of HIV-1 replication and NF- κ B activity by cysteine and cysteine derivatives" *AIDS* (1991) 5:497-503;
147. Miller, H.R. et al., "Reduction of Nonspecific Fluorescence in Respiratory Specimens By Pretreatment with N-Acetylcysteine" *Journal of Clinical Microbiology* (1986) 24:470-471;
148. Mukaida, N. et al., "Novel Mechanism of Glucocorticoid-Mediated Gene Repression", *The Journal of Biological Chemistry* (1994) 269:13289-13295;
149. Nagasawa, K. et al., "Induction of Human Malignant T-Lymphoblastic Cell Lines MOLT-3 and Jurkat by 12-O-Tetradecanoylphorbol-13-Acetate: Biochemical, Physical, and Morphological Characterization" *Journal of Cellular Physiology* (1981) 109:181-192;
150. Norman, A.W. et al., "1,25-Dihydroxycholecalciferol: Identification of the Proposed Active Form of Vitamin D₃ in the Intestine" *Science* (1971) 173:51-54;

Applicants: David Baltimore et al.
Serial No.: 10/037,341
Filed : January 4, 2002
Page 34 of 47

151. Osborn, L. et al., "Tumor necrosis factor α and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor κ B" Proc. Natl. Acad. Sci. USA (1989) 86:2336-2340;
152. Provvedini, D.M. et al., "1,25-Dihydroxyvitamin D₃ Receptors in Human Leukocytes" Science (1983) 221:1181-1183;
153. Reed, J.C. et al., "Effect of Cyclosporin A and Dexamethasone on Interleukin 2 Receptor Gene Expression¹" The Journal of Immunology (1986) 137:150-154;
154. Reed [2], J.C. et al., "Regulation of c-myc mRNA levels in normal human lymphocytes by modulators of cell proliferation" Proc. Natl. Acad. Sci. USA (1985) 82:4221-4224;
155. Rigby [1], W.F.C. et al., "Regulation of Lymphokine Production and Human T Lymphocyte Activation by 1, 25-Dihydroxyvitamin D₃" J. Clin. Invest. (1987) 79:1659-1664;
156. Rigby [2], W.F.C. et al., "The Effects of 1,25-Dihydroxyvitamin D₃ on Human T Lymphocyte Activation and Proliferation: A cell cycle analysis" The Journal of Immunology (1985) 135:2279-2286;
157. Roederer, M. et al., "Cytokine-stimulated human immunodeficiency virus replication is inhibited by N-acetyl-L-cysteine" Proc. Natl. Acad. Sci. USA (1990) 87:4884-4888;
158. Rovera, G. et al., "Induction of Differentiation in Human Promyelocytic Leukemia Cells by Tumor Promoters" Science (1979) 204:868-870;

Applicants: David Baltimore et al.
Serial No.: 10/037,341
Filed : January 4, 2002
Page 35 of 47

159. Ruben and Rosen, "Suppression of Signals Required for Activation of Transcription Factor NF- κ B in Cells Constitutively Expressing the HTLV-I Tax Protein" *The New Biologist* (1990) 2:894-902;
160. Saito [Article], Y. et al., "Possible involvement of a novel protease in neurite outgrowth of PC12 cells" *Neuroscience Research*, Suppl. 13 (1990) S97-S101;
161. Saito [1], Y. et al., "Enhancement of neurite outgrowth in PC12h cells by a protease inhibitor" *Neuroscience Letters* (1988) 89:102-107;
162. Saito [2], Y. et al., "The Neurite-Initiating Effect of a Tripeptide Aldehyde Pretease Inhibitor on PC12h Cells" *J. Biochem.* (1989) 106:1035-1040;
163. Scheinman, R. et al., "Characterization of Mechanisms Involved In Transrepression of NF- κ B by Activated Glucocorticoid Receptors", *Molecular and Cellular Biology* (1995) 15:943-953;
164. Schmidt, A. et al., "Inducible Nuclear Factor Binding to the κ B Elements of the Human Immunodeficiency Virus Enhancer in T Cells Can Be Blocked by Cyclosporin A in a Signal-Dependent Manner", *Journal of Virology* (1990) 64:4037-4041;
165. Schreck [1], R. et al., "Dithiocarbamates as Potent Inhibitors of Nuclear Factor κ B Activation in Intact Cells" *J. Exp. Med.* (1992) 175:1181-1194;
166. Schreck [2], R. et al., "Reactive oxygen intermediates as apparently widely used messengers in the activation of the

Applicants: David Baltimore et al.
Serial No.: 10/037,341
Filed : January 4, 2002
Page 36 of 47

- NF- κ B transcription factor and HIV-1" The EMBO Journal (1991) 10:2247-2258;
167. Semmler, E.J. et al., "The Synthesis of $1\alpha,25$ -Dihydroxycholecalciferol - A Metabolically Active Form of Vitamin D₃" Tetrahedron Letters No. 40 (1972) 4147-4150;
168. Shirakawa and Mizel, "In Vitro Activation and Nuclear Translocation of NF- κ B Catalyzed by Cyclic AMP-Dependent Protein Kinase and Protein Kinase C", Molecular and Cellular Biology (1989) 9:2424-2430;
169. Siebenlist, U. et al., "Promoter Region of Interleukin-2 Gene Undergoes Chromatin Structure Changes and Confers Inducibility on Chloramphenicol Acetyltransferase Gene during Activation of T Cells" Molecular and Cellular Biology (1986) 6:3042-3049;
170. St. Ledger, et al., "Factors Associated With Cardiac Mortality In Developed Countries With Particular Reference To The Consumption of Wine", Public Health, The Lancet (1979) 1017-1020;
171. Staal, F.J.T. et al., "Intracellular Thiols Regulate Activation of Nuclear Factor κ B and Transcription of Human Immunodeficiency Virus", Proc. Natl. Acad. Sci. USA (1990) 87:9943-9947;
172. Tanaka, H. et al., "Sequence-specific interaction of α - β -anomeric double-stranded DNA with the p50 subunit of NF- κ B: application to the decoy approach" Nucleic Acids Research (1994) 22:3069-3074;
173. Thévenin, C. et al., "Induction of Nuclear Factor- κ B and the Human Immunodeficiency Virus Long Terminal Repeat by

Applicants: David Baltimore et al.
Serial No.: 10/037,341
Filed : January 4, 2002
Page 37 of 47

- Okadaic Acid, a Specific Inhibitor of Phosphatases 1 and 2A" The New Biologist (1990) 2:793-800;
174. Tong-Starksen, S.E. et al., "Signaling Through T Lymphocyte Surface Proteins, TCR/CD3 And CD28, Activates The HIV-1 Long Terminal Repeat" The Journal of Immunology (1989) 142:702-707;
175. Tracey, K.J. et al., "Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia" Nature (1987) 330:662-664;
176. Tsoukas, C.D. et al., "1,25-Dihydroxyvitamin D₃: A Novel Immunoregulatory Hormone" Science (1984) 224:1438-1440;
177. Waage and Bakke, "Glucocorticoids suppress the production of tumour necrosis factor by lipopolysaccharide-stimulated human monocytes" Immunology (1988) 63:299-302;
178. Weissmann, G., "Aspirin: After more than 200 years, the mechanisms by which this venerable drug and its relatives achieve their wide range of effects have yet to be fully elucidated" Scientific American Journal (1991) pp. 84-90;
179. Physicians' Desk Reference 1970 24th Edition;
180. Physicians' Desk Reference 1980 34th Edition;
181. Physicians' Desk Reference 1985 39th Edition;
182. June 28, 2007 Deposition of Lynn Corcoran, Ph.D., Pages 1-109, Amgen, Inc. et al. v. Ariad Pharmaceuticals, Inc. et al., D. Del. Civil Action No. 06-259-MPT;
183. July 10, 2007 Deposition of Roger Gregoire Clerc, Ph.D., Pages 1-201, Amgen, Inc. et al. v. Ariad Pharmaceuticals, Inc. et al., D. Del. Civil Action No. 06-259-MPT;

Applicants: David Baltimore et al.
Serial No.: 10/037,341
Filed : January 4, 2002
Page 38 of 47

184. August 7, 2007 Videotaped Deposition of Louis M. Staudt, M.D., Ph.D., Pages 1-275, Amgen, Inc. et al. v. Ariad Pharmaceuticals, Inc. et al., D. Del. Civil Action No. 06-259-MPT;
185. August 20, 2007 Videotaped Deposition of Patrick A. Baeuerle, Ph.D., Vol. I-II, Amgen, Inc. et al. v. Ariad Pharmaceuticals, Inc. et al., D. Del. Civil Action No. 06-259-MPT;
186. June 29, 2007 Wyeth's Response To Ariad's First Set Of Interrogatories (Nos. 1-25), Amgen, Inc. et al. v. Ariad Pharmaceuticals, Inc. et al., D. Del. Civil Action No. 06-259-MPT;
187. July 9, 2007 Ariad And The Institutions' Responses And Objections To Amgen Entities' Second Set Of Interrogatories, Amgen, Inc. et al. v. Ariad Pharmaceuticals, Inc. et al., D. Del. Civil Action No. 06-259-MPT;
188. August 17, 2007 Wyeth's Supplemental Responses To Ariad's First Set Of Interrogatories (Nos. 1-25), Amgen, Inc. et al. v. Ariad Pharmaceuticals, Inc. et al., D. Del. Civil Action No. 06-259-MPT;
189. September 10, 2007 Wyeth's Second Set of Supplemental Responses To Ariad's First Set Of Interrogatories (Nos. 1-25), Amgen, Inc. et al. v. Ariad Pharmaceuticals, Inc. et al., D. Del. Civil Action No. 06-259-MPT;
190. Annual Meeting, J. Am. Med. Assoc. (1963) 183:166-169;
191. Baeuerle and Baltimore, "I κ B: A Specific Inhibitor of the NF- κ B Transcription Factor", Science (1988a) 242:540-546;

Applicants: David Baltimore et al.
Serial No.: 10/037,341
Filed : January 4, 2002
Page 39 of 47

192. Baeuerle and Baltimore, "Activation of DNA-Binding Activity in an Apparently Cytoplasmic Precursor of the NF- κ B Transcription Factor", *Cell* (1988b) 53:211-217;
193. Baeuerle and Baltimore, "Phorbol-ester-induced Activation of the NF- κ B Transcription Factor Involves Dissociation of an Apparently Cytoplasmic NF- κ B/Inhibitor Complex", *Cold Spring Harbor Symposia* (1988c) LIII:789-798;
194. Baltimore and Sharp, "Binding of a Nuclear Factor to a Regulatory Sequence in the Promoter of The Mouse H-2K^b Class I Major Histocompatibility Gene", *Molecular and Cellular Biology* (1987) 7:305-313;
195. Baltimore, D., "Intracellular immunization", *Nature* (1988) 335:395-396;
196. Banerji, S.S. et al., "The Immunosuppressant FK-506 Specifically Inhibits Mitogen-Induced Activation of the Interleukin-2 Promoter and the Isolated Enhancer Elements NFIL-2A and NF-AT1", *Molecular and Cellular Biology* (1991) 11:4074-4087;
197. Blonar, M.A. et al., "A gamma-interferon-induced factor that binds the interferon response sequence of the MHC class I gene, H-2K^b", *The EMBO Journal* (1989) 8:1139-1144;
198. Bohnlein E. et al., "The Same Inducible Nuclear Proteins Regulates Mitogen Activation of Both the Interleukin-2 Receptor-Alpha Gene and Type 1 HIV", *Cell* (1988) 53:827-836;
199. Clouse, K.A. et al., "Monokine Regulation of Human Immunodeficiency Virus-1 Expression in a Chronically

Applicants: David Baltimore et al.
Serial No.: 10/037,341
Filed : January 4, 2002
Page 40 of 47

- Infected Human T Cell Clone", The Journal of Immunology (1989) 142:431-438;
200. Collart, M.A. et al., "Modulations of Functional Activity in Differentiated Macrophages are Accompanied by Early And Transient Increase or Decrease in c-FOS Gene Transcription", The Journal of Immunology (1987) 139:949-955;
201. Collart, M.A. et al., "Regulation of Tumor Necrosis Factor Alpha Transcription in Macrophages: Involvement of Four κ B-Like Motifs and of Constitutive and Inducible Forms of NF- κ B", Molecular and Cellular Biology (1990) 10:1498-1506;
202. Cross, S.L. et al., "Functionally Distinct NF- κ B Binding Sites in the Immunoglobulin κ and IL-2 Receptor α Chain Genes", Science (1989) 244:466-469;
203. Davis, N. et al., "Rel-Associated pp40: An Inhibitor of the Rel Family of Transcription Factors", Science (1991) 253:1268-1271;
204. Dew, M.J. et al., "Maintenance of remission in ulcerative colitis with 5-amino salicylic acid in high doses by mouth", British Medical Journal (1983) 287:23-24;
205. Dofferhoff, A.S.M., et al., "Effects of Different Types and Combinations of Antimicrobial Agents on Endotoxin Release from Gram-negative Bacteria: An In-Vitro and In-Vivo Study", Scandinavian Journal of Infectious Diseases (1991) 23:745-754;
206. Fan, Chen-Ming and Maniatis, T., "Two different virus-inducible elements are required for human β -interferon gene regulation", The EMBO Journal (1989) 8:101-110;

Applicants: David Baltimore et al.
Serial No.: 10/037,341
Filed : January 4, 2002
Page 41 of 47

207. Fan, Chen-Ming and Maniatis, T., "A DNA-binding protein containing two widely separated zinc finger motifs that recognize the same DNA sequence", *Genes and Development* (1990) 4:29-42;
208. Fan, Chen-Ming and Maniatis, T., "Generation of p50 subunit of NF- κ B by processing of p105 through an ATP-dependent pathway", *Nature* (1991) 354:395-398;
209. Friedman, A.D. et al., "Expression of a truncated viral trans-activator selectively impedes lytic infection by its cognate virus", *Nature* (1988) 335:452-454;
210. Gehrt, A. Et al., "Cycloepoxydon, 1-Hydroxy-2-hydroxymethyl-3-pent-1-enylbenzene and 1-Hydroxy-2-hydroxymethyl-3-pent-1, 3-dienylbenzene, New Inhibitors of Eukaryotic Signal Transduction", *The Journal of Antibiotics* (1998) 51:455-463;
211. Goldfelf, A.E. and Maniatis, T., "Coordinate viral induction of tumor necrosis factor α and interferon β cells and monocytes", *Proc. Natl. Acad. Sci. USA* (1989) 86:1490-1494;
212. Goldfeld, A. E. et al., "Human tumor necrosis factor α gene regulation by virus and lipopolysaccharide", *Proc. Natl. Acad. Sci. USA* (1990) 87:9769-9773;
213. Goodbourn, S. And Maniatis, T., "Overlapping positive and negative regulatory domains of the human β -interferon gene", *Proc. Natl. Acad. Sci. USA* (1988) 85:1447-1451;
214. Haskill, S. et al., "Characterization of an Immediate-Early Gene Induced in Adherent Monocytes That Encodes I κ B-like Activity", *Cell* (1991) 65:1261-1289;

Applicants: David Baltimore et al.
Serial No.: 10/037,341
Filed : January 4, 2002
Page 42 of 47

215. Horuk, R., "A rapid and direct method for the detection and quantification of interleukin-1 receptors using 96 well filtration plates", Journal of Immunological Methods (1989) 119:255-258;
216. Hurley, J.C. et al., "Antibiotic-Induced Release of Endotoxin in Chronically Bacteriuric Patients", Antimicrobial Agents and Chemotherapy (1991) 35:2388-2394;
217. Keller, A.D. and Maniatis, T., "Identification of an inducible factor that binds to a positive regulatory element of the human β -interferon gene", Proc. Natl. Acad. Sci. USA (1988) 85:3309-3313;
218. Kerr, L.D. et al., "The Rel-associated pp40 protein prevents DNA binding of Rel and NF- κ B: relationship with I κ B β and regulation by phosphorylation", Genes and Development (1991) 5:1464-1476;
219. St. Ledger, A.S. et al., "Factors Associated With Cardiac Mortality In Developed Countries With Particular Reference To The Consumption of Wine", The Lancet (1979) 1017-1020;
220. Lenardo, M. et al., "Protein-Binding Sites in Ig Gene Enhancers Determine Transcriptional Activity and Inducibility", Science (1987) 236:1573-1577;
221. Lenardo, M.J. et al., "NF- κ B protein purification from bovine spleen: Nucleotide stimulation and binding site specificity", Proc. Natl. Acad. Sci. USA (1988) 85:8825-8829;
222. Lenardo, M.J. et al., "The Involvement of NF- κ B in β -Interferon Gene Regulation Reveals Its Role as Widely

Applicants: David Baltimore et al.
Serial No.: 10/037,341
Filed : January 4, 2002
Page 43 of 47

- Inducible Mediator of Signal Transduction", Cell (1989) 57:287-294;
223. Leung, K. and Nabel, G., "HTLV-1 transactivator induces interleukin-2 receptor expression through an NF- κ B-like factor", Nature (1988) 333:776-778;
224. Logeat, F. et al., "Inhibition of transcription factors belonging to the rel/NF- χ B family by a transdominant negative mutant", The EMBO Journal (1991) 10:1827-1832;
225. Mauxion, F. et al., "Comparison of constitutive and inducible transcriptional enhancement mediated by κ B-related sequences: Modulation of activity in B cells by human T-cell leukemia virus type I tax gene", Proc. Natl. Acad. Sci. USA (1991) 88:2141-2145;
226. Mauxion, F. And Sen, R., "Alteration of a Single Nucleotide Allows Efficient Binding of H2TF1/KBF1 to the Immunoglobulin κ Enhancer B Motif", Molecular and Cellular Biology (1989) 9:3548-3552;
227. Mustafa, M.M. et al., "Increased Endotoxin and Interleukin- 1β Concentrations in Cerebrospinal Fluid of Infants with Coliform Meningitis and Ventriculitis Associated with Intraventricular Gentamicin Therapy", The Journal of Infectious Diseases (1989) 160:891-895;
228. Nabel, G. and Baltimore, D., "An inducible transcription factor activates expression of human immunodeficiency virus in T cells", Nature (1987) 326:711-713;
229. Nelsen, B. et al., "The NF- κ B-Binding Site Mediates Phorbol Ester-Inducible Transcription in Nonlymphoid Cells", Molecular and Cellular Biology (1988) 8:3526-3531;

Applicants: David Baltimore et al.
Serial No.: 10/037,341
Filed : January 4, 2002
Page 44 of 47

230. Rigby, W.F.C. et al., "Inhibition of T Lymphocyte Mitogenesis by 1,25-Dihydroxyvitamin D₃ (Calcitriol)", J. Clin. Invest. (1984) 74:1451-1455;
231. Rigby, W.F.C. et al., "The Effects of 1,25-Dihydroxyvitamin D₃ on Human T Lymphocyte Activation And Proliferation: A Cell Cycle Analysis", The Journal of Immunology (1985) 135:2279-2286;
232. Ruben, S. et al., "Cellular Transcription Factors and Regulation of IL-2 Receptor Gene Expression by HTLV-1 tax Gene Product", Science (1988) 241:89-92;
233. Schmitz, M.F., et al., "Proteins controlling the nuclear uptake of NF- κ B, Rel and dorsal", Trends in Cell Biology (1991) 1:130-137;
234. Schreck, R. and Baeuerle, P., "A role for oxygen radicals as second messengers", Trends in Cell Biology (1991) 1:39-42;
235. Sen, R. and Baltimore, D., "Multiple Nuclear Factors Interact with the Immunoglobulin Enhancer Sequences", Cell (1986) 46:705-716;
236. Sen, R. and Baltimore, D., "Inducibility of κ Immunoglobulin Enhancer-Binding Protein NF- κ B by a Posttranslational Mechanism", Cell (1986) 47:921-928;
237. Shenep, J.L. and Mogan, K.A., "Kinetics of Endotoxin Release During Antibiotic Therapy For Experimental Gram-Negative Bacterial Sepsis", The Journal of Infectious Diseases (1984) 150:380-388;
238. Scott, J.K. and Smith, G.P., "Searching for Peptide Ligands with an Epitope Library", Science (1990) 249:386-390;

Applicants: David Baltimore et al.
Serial No.: 10/037,341
Filed : January 4, 2002
Page 45 of 47

239. Tomita, T. et al., "Suppressed Severity of Collagen-Induced Arthritis By In Vivo Transfection of Nuclear Factor κ B Decoy Oligodeoxynucleotides As A Gene Therapy", Arthritis & Rheumatism (1999) 42:2532-2542;
240. Yu, Xiao-Peng et al., "down-regulation of NF- κ B protein levels in activated human lymphocytes by 1,25-dihydroxyvitamin D₃", Proc. Natl. Acad. Sci. USA (1995) 92:10990-10994;
241. Zabel, U., and Baeuerle, P.A., "Purified Human I κ B Can Rapidly Dissociate the Complex of the NF- κ B Transcription Factor with Its Cognate DNA", Cell (1990) 61:255-265; and
242. Zinn, K. et al., "Identification of Two Distinct Regulatory Regions Adjacent to the Human β -Interferon Gene", Cell (1983) 34:865-879;
243. July 16, 2007 Memorandum In Support of Eli Lilly And Company's Motion To Stay Entry of Judgement Pending Reexamination or For Settlement of Form of Final Judgement, Document 409, filed 07/16/2007, pgs. 1-18 in Civil Case 02 CV 11280 RWZ;
244. August 22, 2007 Reply Memorandum In Support of Eli Lilly And Company's Motion To Stay Entry of Judgement Pending Reexamination or For Settlement of Form of Final Judgement, Document 414, filed 08/22/2007, pgs. 1-11, including Exhibits 2-6 in Civil Case 02 CV 11280 RWZ;
245. September 10, 2007 Final Judgement, Document 417, filed 09/10/2007, pgs. 1-5 in Civil Case 02 CV 11280 RWZ;
246. September 23, 2007 Memorandum In Support of Defendant's Renewed Motion For Judgment As A Matter Of Law Or, In The

Applicants: David Baltimore et al.
Serial No.: 10/037,341
Filed : January 4, 2002
Page 46 of 47

Alternative, A New Trial, Document 420, filed 09/23/2007, pgs. 1-53, including Exhibit 2 in Civil Case 02 CV 11280 RWZ;


247. July 16, 2007 Declaration Of Laura P. Masurovsky For Eli Lilly And Company's Motion To Stay Entry Of Judgment Pending Reexamination Or For Settlement Of Form of Final Judgment, Document 410, filed 07/16/2007, pgs. 1-2, including Exhibits 2-13 in Civil Case 02 CV 11280 RWZ; and
248. July 26, 2007 Plaintiffs' Opposition To Lilly's Motion To Stay Entry Of Judgment Pending Reexamination or for Settlement of Form of Final Judgement, Document 411, filed 07/26/2007, pgs. 1-11, including Exhibit 2 in Civil Case 02 CV 11280 RWZ.

If a telephone interview would be of assistance in advancing prosecution of the subject application, Applicants' undersigned attorney invites the Examiner to telephone him at the number provided below.

Applicants: David Baltimore et al.
Serial No.: 10/037,341
Filed : January 4, 2002
Page 47 of 47

No fee, other than the enclosed \$1,050.00 fee for a three-month extension of time and the \$180.00 fee for filing a Supplemental Information Disclosure Statement, is deemed necessary in connection with the filing of this Amendment. Accordingly, a check for \$1,230.00 is enclosed. However, if any fee is required, authorization is hereby given to charge the additional amount of any such fee to Deposit Account No. 03-3125.


Respectfully submitted,



John P. White
Registration No. 28,678
Gary J. Gershik
Registration No. 39,992
Attorneys for Applicants
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


Gary J. Gershik
Reg. No. 39,992

Date